ValueScreener

ValueScreener company report

Evotec SE (EVO)

NASDAQ / Healthcare / Drug Manufacturers - Specialty & Generic

Share price

1.42 USD Market dataClose of Oct 15, 2026

Market capitalisation

504.4M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2024, filed Apr 17, 2025
Ratios computed
Oct 15, 2026
Filed years
6, FY2019 to FY2024
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-20.6% Computed

From the FY2024 filing

Read quality

Valuation

Price to book

0.47x Computed

FY2024 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-22.1% Computed

FY2024 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

FY2015 Revenue: 127.7M EURFY2015 Net income: 16.5M EURFY2016 Revenue: 164.5M EURFY2016 Net income: 27.5M EURFY2017 Revenue: 257.6M EURFY2017 Net income: 24.3M EURFY2018 Revenue: 375.4M EURFY2018 Net income: 84.2M EURFY2019 Revenue: 446.4M EURFY2019 Net income: 38.2M EURFY2020 Revenue: 500.9M EURFY2020 Net income: 6.3M EURFY2021 Revenue: 618.0M EURFY2021 Net income: 215.5M EURFY2022 Revenue: 751.4M EURFY2022 Net income: -175.7M EURFY2023 Revenue: 781.4M EURFY2023 Net income: -83.9M EURFY2024 Revenue: 797.0M EURFY2024 Net income: -196.1M EUR
Revenue Net income10 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
2 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -20.6% in FY2024, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Drug Manufacturers - Specialty & Generic industry (57 companies), -20.6% sits at the 39th percentile; the middle half of that group runs from -35.9% to 7.5%.

Is it safe

Debt to equity was 0.46 in FY2024, in the band labelled "Conservative" (below 0.50), on lines anchored on Graham's defensive-investor criteria, suggesting a balance sheet that relies little on borrowing.

Today, against the Drug Manufacturers - Specialty & Generic industry (33 companies), 0.46 sits at the 62nd percentile; the middle half of that group runs from 0.10 to 0.60.

Year by year against peers
Whether Evotec SE's return on equity stayed above the median of the Drug Manufacturers - Specialty & Generic industry, year by year. (FY2020 to FY2024, 5 fiscal years of Evotec SE with a comparable figure)
The direction
Which way Evotec SE's gross margin has moved, and how steadily. (FY2015 to FY2024, 10 filed years of Evotec SE)
What could explain it
What in Evotec SE's filed statements could explain the movements. (4 readings drawn from the statement lines Evotec SE filed)
What to check next
What to check next on Evotec SE, and where in its filings. (3 questions for Evotec SE)
In one paragraph
One paragraph on Evotec SE's returns, cash, balance sheet and price. (8 of sixteen figures read for Evotec SE)

These are EVO’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research EVOPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2024 annual report: 20-F, filed Apr 17, 2025, accession 0001104659-25-035638.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Evotec SE: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.

n/a ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Return on equity-20.6% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Return on capital employed, pre-tax-9.1% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Return on assets-10.3% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Gross margin14.4% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Operating margin-17.9% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Net margin-24.6% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
EVO -24.6%
EOLS -17.4%HROW -1.9%TLRY -13.3%AQST -188.1%IRWD 8.1%
-188.1%8.1%
Net margin: EVO against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Evotec SE: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity0.46 ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Current ratio1.98 ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Quick ratio1.89 ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Altman Z-score0.17 ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Net debt133.0M ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Total assets 1.91BTotal liabilities 960.0MShareholders' equity 952.5MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Evotec SE owned and owed at the end of fiscal 2024, from the balance sheet it filed (20-F, filed Apr 17, 2025, 0001104659-25-035638).

Evotec SE: balance sheet position
Total assets1.91B FiledFY2024 20-F, filed Apr 17, 2025
Total liabilities960.0M FiledFY2024 20-F, filed Apr 17, 2025
Shareholders' equity952.5M FiledFY2024 20-F, filed Apr 17, 2025
Cash306.4M FiledFY2024 20-F, filed Apr 17, 2025
Total debt439.4M FiledFY2024 20-F, filed Apr 17, 2025
Net debt133.0M
Current ratio1.98
Debt to equity0.46
  • Interest cover: FY2024: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Evotec SE: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book0.47x ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Price to sales0.56x ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Enterprise value to EBITDA
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Diluted earnings per share
Why n/a

The FY2024 filing carries no diluted earnings per share we could read.

n/a FiledFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638

We publish no fair value or price target of our own. Value EVO on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Evotec SE today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Evotec SE: valuation
Share price1.42 USD
Market capitalisation504.4M USD
Enterprise value to EBITDAn/a
Graham numbern/m
Diluted earnings per share, FY2018n/a

Diluted earnings per share, FY2018: Filed before the 4-for-1 split on 20 Oct 2021, and the filing it was read from cannot be placed against it, so it is not put on today's share count and is not shown beside figures that are.

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like Evotec SE

  1. Evolus, Inc. (EOLS)Market cap 500.0M USD
  2. Harrow Health, Inc. (HROW)Market cap 1.08B USD
  3. Tilray Brands, Inc. (TLRY)Market cap 359.0M USD
  4. Aquestive Therapeutics, Inc. (AQST)Market cap 509.6M USD
  5. Ironwood Pharmaceuticals, Inc. (IRWD)Market cap 623.0M USD

Same industry (Drug Manufacturers - Specialty & Generic) and size band (Small, 300M to 2B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Evotec SE: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-22.1% ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Free cash flow-99.2M EUR ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Free cash flow margin-12.4% ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
FY2015 Free cash flow: 4.2M EURFY2015 Net income: 16.5M EURFY2016 Free cash flow: 57.2M EURFY2016 Net income: 27.5M EURFY2017 Free cash flow: -6.8M EURFY2017 Net income: 24.3M EURFY2018 Free cash flow: 128.4M EURFY2018 Net income: 84.2M EURFY2019 Free cash flow: 10.9M EURFY2019 Net income: 38.2M EURFY2020 Free cash flow: -54.4M EURFY2020 Net income: 6.3M EURFY2021 Free cash flow: 7.7M EURFY2021 Net income: 215.5M EURFY2022 Free cash flow: 24.5M EURFY2022 Net income: -175.7M EURFY2023 Free cash flow: -176.9M EURFY2023 Net income: -83.9M EURFY2024 Free cash flow: -99.2M EURFY2024 Net income: -196.1M EUR
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Evotec SE: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2024Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.47xFY2024Oct 15, 2026
n/aFY2024Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-22.1%FY2024Oct 15, 2026
n/aFY2024Apr 17, 2025
n/a The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
n/aFY2024Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
0.46FY2024Apr 17, 2025
1.98FY2024Apr 17, 2025
0.56xFY2024Oct 15, 2026
n/mFY2024Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.17FY2024Oct 15, 2026
-1.70FY2024Apr 17, 2025
4/9FY2024Apr 17, 2025

The figures are computed from the accounts for fiscal 2024, the newest full year on file. 6 filed fiscal years on record, FY2019 to FY2024, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 fiscal years, FY2015 to FY2024. 6 read from the annual reports Evotec SE filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in EUR, as reported.

Evotec SE: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2024797.0M-142.5M-196.1Mn/a-99.2M-17.9%-20.6%20-F, Apr 17, 20250001104659-25-035638
FY2023781.4M-47.5M-83.9Mn/a-176.9M-6.1%-7.5%20-F, Aug 14, 20240001104659-24-089121
FY2022751.4M20.9M-175.7Mn/a24.5M2.8%-14.8%20-F, May 12, 20230001104659-23-059900
FY2021618.0M41.0M215.5Mn/a7.7M6.6%15.6%20-F, Apr 26, 20220001104659-22-049929
FY2020500.9M48.6M6.3Mn/a-54.4M9.7%0.9%20-F, Apr 26, 20220001104659-22-049929
FY2019446.4M62.7M38.2Mn/a10.9M14.1%n/a20-F, Apr 26, 20220001104659-22-049929
FY2018375.4M77.5M84.2Mn/a128.4M20.6%19.9%Market data, supplied Oct 15, 2026accession n/a
FY2017257.6M37.5M24.3Mn/a-6.8M14.6%7.3%Market data, supplied Oct 15, 2026accession n/a
FY2016164.5M31.3M27.5Mn/a57.2M19.1%12.9%Market data, supplied Oct 15, 2026accession n/a
FY2015127.7M11.6M16.5Mn/a4.2M9.1%8.9%Market data, supplied Oct 15, 2026accession n/a
  • Revenue, compound annual growth FY2015 to FY2024: 22.6%
  • Earnings: Earnings was not positive in both 2015 and 2024, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Fewer than two filed years carry earnings per share.
  • Free cash flow: Free cash flow was not positive in both 2015 and 2024, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Evotec SE: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-1.70 ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Piotroski F-score4/9 ComputedFY2024 20-F, filed Apr 17, 2025, 0001104659-25-035638
Named tests met2 of 30 Computed
Beta1.18 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 2 met, 22 not met, 6 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
Book or below, low debt (Walter Schloss); Cheapest quarter on P/B (David Dreman)
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC
Not measured
Earnings yield and ROIC (Joel Greenblatt); ROIC at or above WACC; P/E times P/B (Benjamin Graham); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(15)
  • Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • EV/EBITDA: We do not hold this figure for this company, so there is nothing to show.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 15 figures could not be read on this company, among them Positive Earnings Streak, P/E Ratio, EV/EBIT. Each blank in the table above names the rest, with its reason. 6 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 6 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy